Dosing Guidelines - octaplas Official Website

Dosing is consistent with that for fresh frozen plasma¹

Indication	Dosage	Infusion Rate
Replacement of multiple coagulation factors in patients with acquired deficiencies	10 to 15 milliliters per kg (Adjust the dose based on the desired clinical response)	<1 mL/kg/min
Plasma exchange in patients with TTP	1 to 1.5 plasma volumes (40 to 60 milliliters per kg)	<1 mL/kg/min

Octaplas is for intravenous use only
Administer Octaplas based on AB0-blood group compatibility

For replacement of coagulation factors in patients with acquired deficiencies:

At the recommended dosage, initially octaplas should increase the patient’s plasma coagulation factor levels by approximately 15 to 25%
If hemostasis is not achieved, use higher doses
Adjust dose based on desired clinical response
Monitor response, including measurement of activated partial thromboplastin time (aPTT), prothrombin time (PT), and/or specific coagulation factors

Administration and handling¹

Administer octaplas after thawing using an infusion set with a filter
Octaplas should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if turbid.
Avoid shaking
Do not refreeze thawed product
Discard unused product

Steps for thawing

Flow chart explaining Water Bath system for Octaplas

Flow chart explaining the dry tempering system for Octaplas

Reference:

Octaplas Full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.

Indications and Important Safety Information for octaplas^®, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion

Please see octaplas full Prescribing Information.

Indications and Important Safety Information for octaplas^®, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion

Please see octaplas full Prescribing Information.

Indications and Usage

Octaplas^® is a solvent/detergent (S/D) treated, pooled human plasma indicated for replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or who are undergoing cardiac surgery or liver transplantation; and plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

Contraindications

Octaplas is contraindicated in patients with immunoglobulin A (IgA) deficiency; severe deficiency of protein S; history of hypersensitivity to fresh frozen plasma or to plasma-derived products including any plasma protein; or a history of hypersensitivity reaction to octaplas.

Warnings and Precautions

Transfusion reactions can occur with ABO blood group mismatches. Administration of octaplas must be based on ABO-blood group compatibility. High infusion rates can induce hypervolemia with consequent pulmonary edema or cardiac failure. Excessive bleeding due to hyperfibrinolysis can occur due to low levels of alpha2-antiplasmin (also named plasmin inhibitor). Thrombosis can occur due to low levels of Protein S. Citrate toxicity can occur with volumes exceeding one milliliter of octaplas per kg per minute. octaplas is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Adverse Reactions

The most common adverse reactions observed in ≥ 1% of patients included pruritus, urticaria, nausea, headache, paresthesia. Serious adverse reactions seen in clinical trials were anaphylactic shock, citrate toxicity and severe hypotension.

Please see octaplas full Prescribing Information

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs)